Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. PLEASE, JUST THE FACTS ON PHARMACY COUNTS… When it comes to
(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement on the Pennsylvania Auditor General’s report, “Bringing Transparency & Accountability to Drug Pricing:” “The Pennsylvania Auditor General has released yet another biased report on pharmacy benefit managers (PBMs).
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
(Washington, D.C.) — The Pennsylvania Auditor General’s report on Medicaid and pharmacy benefit managers (PBMs) is undermined by failing to note a simple, but key critical element: PBMs are reducing prescription drug costs and increasing access to needed treatments for
(Washington, D.C.) — As the Administration considers modifying price concessions for prescription drugs in Medicare and federal programs, the Pharmaceutical Care Management Association (PCMA) is releasing new data, “Reconsidering Drug Prices, Rebates, and PBMs,” showing drug manufacturers alone set prices –
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
JC Scott (00:08): Welcome to the Pharmacy Benefit, a podcast where we talk about issues impacting patients, consumers, and affordable access to prescription drugs and better healthcare through the work being done by pharmacy benefit managers or PBMs. I’m
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
With a nod to Dickens given that it’s the holidays, I’ve been thinking about biosimilars past, present and future lately. In that holiday spirit, even though the parallels aren’t perfect to the classic holiday story, let’s look at the biosimilar
(Washington, D.C.) — As independent drugstore lobbyists descend on Harrisburg for their lobby day, the Pharmaceutical Care Management Association (PCMA) released the following statement: “Pharmacy benefit managers (PBMs) advocate on behalf of Pennsylvania’s consumers and health plan sponsors by negotiating with drug manufacturers and
©2024 PCMA. All Rights Reserved.
